Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
- Resource Type
- Source
- Investigational New Drugs.
- Subject
Pharmacology Oncology Pharmacology (medical) - Language
- ISSN
- 1573-0646
0167-6997